Is Iluvien From Alimera Sciences the Future of Ophthalmic Drug Delivery?
July 27, 2010
I have just written and placed online an in-depth writeup about a new drug delivery system, that should obtain FDA marketing approval by the end of this year. It has the potential to treat diabetic macular edema for up to three years.
The drug system is called Iluvien and is from Alimera Sciences. Iluvien is a tiny, extended release intravitreal insert (the size of a grain of rice), that provides a method to deliver fluocinolone acetonide (FA), a corticosteroid, to the retina for up to three years for treatment for diabetic macular edema (DME). It is one a group of new ophthalmic sustained drug delivery systems that are currently on or about to enter the market for treating ophthalmic diseases, especially in the retina.
In addition to the story of Iluvien, I have listed a group of sustained drug delivery system under development for various other ophthalmic diseases.
Here is the link to my writeup: http://tinyurl.com/Iluvien
You might also enjoy...
- Intravitreal Drug Delivery System Okay for Diabetic Macular Edema
- Icon Biosciences Starting New Trials of Sustained Release Drug Delivery for Post-Op Cataract Patients
- Alimera Sciences Announces Study of Iluvien® in Patients With Macular Edema Due to Retinal Vein Occlusion
- pSivida Announces Positive Results From The Two Phase 3 FAME™ Trials of Iluvien in Patients With Diabetic Macular Edema
- Roche and Genentech Strike Deal With Surmodics For Biodegradable Microparticle Drug Delivery System for Lucentis
Jump down to form below to submit your own comments